Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

NCT04093167 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT04093167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04093167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 26, 2020
Completion date
July 30, 2027
Enrollment
53 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer